Some of the well-known ones include: Ozempic (semaglutide): Approved in 2017 for type 2 diabetes, also commonly used off-label for weight management
Swissmedic approved Eli Lillys Mounjaro (tirzepatide) for type 2 diabetes in 2022 and for weight management in 2024
Data from the ORION study, presented at the Obesity Medicine Associations 2026 annual conference, showed that oral semaglutide 25 mg was associated with significantly greater mean weight loss than orforglipron in a population-adjusted indirect treatment comparison
There is no confirmed date
Although some studies have found that GIP on its own can trigger weight gain, when combined with GLP-1 agonists, it has been found to have profound weight loss benefits
Physical activity can improve colon motility, and the movement from exercise can mechanically stimulate the gut